Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $2.0 million.

  • Viking Therapeutics' Amortizatization of Intangibles fell 5924.88% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 2731.84%. This contributed to the annual value of $17.3 million for FY2024, which is 11052.18% up from last year.
  • Per Viking Therapeutics' latest filing, its Amortizatization of Intangibles stood at $2.0 million for Q3 2025, which was down 5924.88% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Amortizatization of Intangibles ranged from a high of $5.4 million in Q2 2024 and a low of -$1.1 million during Q1 2021
  • Over the past 5 years, Viking Therapeutics' median Amortizatization of Intangibles value was $2.0 million (recorded in 2023), while the average stood at $1.5 million.
  • In the last 5 years, Viking Therapeutics' Amortizatization of Intangibles plummeted by 11184.31% in 2021 and then surged by 499811.32% in 2023.
  • Over the past 5 years, Viking Therapeutics' Amortizatization of Intangibles (Quarter) stood at -$755000.0 in 2021, then soared by 107.02% to $53000.0 in 2022, then soared by 4998.11% to $2.7 million in 2023, then surged by 49.19% to $4.0 million in 2024, then plummeted by 49.67% to $2.0 million in 2025.
  • Its Amortizatization of Intangibles was $2.0 million in Q3 2025, compared to $2.4 million in Q2 2025 and $3.1 million in Q1 2025.